{"id":447834,"date":"2021-03-02T02:03:04","date_gmt":"2021-03-02T07:03:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=447834"},"modified":"2021-03-02T02:03:04","modified_gmt":"2021-03-02T07:03:04","slug":"transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/","title":{"rendered":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences<\/b><\/p>\n<p>STRASBOURG, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:\n<\/p>\n<p><b>Transgene (Euronext Paris: TNG), <\/b>a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that<b \/>members of Transgene\u2019s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>ESMO Targeted Anticancer Therapies Congress 2021<\/b> which will take place March 2-4:\n<p>\u00c9ric Qu\u00e9m\u00e9neur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session &#8216;Where next with Oncolytics&#8217;<i \/>about <b><i>Antibody armed oncolytic viruses<\/i><\/b> (ID 42)<br \/>\n<br \/>Date &amp; Time: March 3<sup>rd<\/sup> at 4.20pm (CET)\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Royal Society Meeting on &#8216;Immuno-oncology: How to get the immune system to beat cancer&#8217; <\/b>which will take place March 24-25:\n<p>This Royal Society meeting will explore immuno-oncology therapies &#8211; both current and recent technologies. Eric Qu\u00e9m\u00e9neur will participate in the <b>immuno-oncology breakthroughs session.<br \/>\n<br \/><\/b>Date &amp; Time: March 24<sup>th<\/sup> at 3.50pm (GMT)\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>4th Annual European Neoantigen Summit<\/b> which will take place April 20-22:\n<p>Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines, will be speaking about <b><i>TG4050: Viral immunotherapy meets AI technology<br \/>\n<br \/><\/i><\/b>Date &amp; Time: April 22<sup>nd<\/sup> at 1pm (CET)\n<\/li>\n<\/ul>\n<p><b><i>About Transgene<br \/>\n<br \/><\/i><\/b>Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.\n<\/p>\n<p>\nThe Company\u2019s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the <i>myvac<\/i><sup>\u00ae<\/sup> platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO\u2122 platform).\n<\/p>\n<p>\nWith Transgene\u2019s <i>myvac<\/i><sup>\u00ae<\/sup> platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The <i>myvac<\/i><sup>\u00ae<\/sup> approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.\n<\/p>\n<p>\nWith its proprietary platform Invir.IO\u2122, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u2122 collaboration with AstraZeneca.\n<\/p>\n<p>\nAdditional information about Transgene is available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.transgene.fr&amp;esheet=52388325&amp;newsitemid=20210301005977&amp;lan=en-US&amp;anchor=www.transgene.fr&amp;index=1&amp;md5=b616f5dc657f6c584629073a4e6919ba\">www.transgene.fr<\/a> \/\/ Follow us on Twitter: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Ftransgenesa&amp;esheet=52388325&amp;newsitemid=20210301005977&amp;lan=en-US&amp;anchor=%40TransgeneSA&amp;index=2&amp;md5=3960452e9242fef2174948604fa6ed29\">@TransgeneSA<\/a><\/p>\n<p><b><i>Disclaimer<br \/>\n<br \/><\/i><\/b><i>This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=52388325&amp;newsitemid=20210301005977&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=3&amp;md5=ca2f702f50ee63971491b6631f7d04e3\">http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.transgene.fr&amp;esheet=52388325&amp;newsitemid=20210301005977&amp;lan=en-US&amp;anchor=www.transgene.fr&amp;index=4&amp;md5=d732cc409679709c63547281ffde25be\">www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210301005977\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210301005977\/en\/<\/a><\/span><\/p>\n<p><b>Transgene:<br \/>\n<\/b><br \/><b>Lucie Larguier<br \/>\n<\/b><br \/>Director Corporate Communications &amp; IR<br \/>\n<br \/>+33 (0)3 88 27 91 04<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investorrelations@transgene.fr\">investorrelations@transgene.fr<\/a><\/p>\n<p><b>Media: Citigate Dewe Rogerson<br \/>\n<\/b><br \/><b>David Dible\/Sylvie Berrebi<br \/>\n<\/b><br \/>+44 (0)20 7638 9571<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:transgene@citigatedewerogerson.com\">transgene@citigatedewerogerson.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210301005977\/en\/255636\/3\/logo_TRANSGENE.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces thatmembers of Transgene\u2019s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences: ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4: \u00c9ric Qu\u00e9m\u00e9neur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session &#8216;Where next with Oncolytics&#8217;about Antibody armed oncolytic viruses (ID 42) Date &amp; Time: March 3rd at 4.20pm (CET) Royal Society Meeting on &#8216;Immuno-oncology: How to get the immune system to beat cancer&#8217; which will take place March 24-25: This Royal Society meeting will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-447834","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces thatmembers of Transgene\u2019s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences: ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4: \u00c9ric Qu\u00e9m\u00e9neur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session &#8216;Where next with Oncolytics&#8217;about Antibody armed oncolytic viruses (ID 42) Date &amp; Time: March 3rd at 4.20pm (CET) Royal Society Meeting on &#8216;Immuno-oncology: How to get the immune system to beat cancer&#8217; which will take place March 24-25: This Royal Society meeting will &hellip; Continue reading &quot;Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T07:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences\",\"datePublished\":\"2021-03-02T07:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/\"},\"wordCount\":641,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/\",\"name\":\"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-02T07:03:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk","og_description":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces thatmembers of Transgene\u2019s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences: ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4: \u00c9ric Qu\u00e9m\u00e9neur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session &#8216;Where next with Oncolytics&#8217;about Antibody armed oncolytic viruses (ID 42) Date &amp; Time: March 3rd at 4.20pm (CET) Royal Society Meeting on &#8216;Immuno-oncology: How to get the immune system to beat cancer&#8217; which will take place March 24-25: This Royal Society meeting will &hellip; Continue reading \"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-02T07:03:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences","datePublished":"2021-03-02T07:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/"},"wordCount":641,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/","name":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-02T07:03:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210301005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=447834"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447834\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=447834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=447834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=447834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}